2. The Stent of Choice in ACS patients

3. The Stent of Choice in ACS 1) The Rationale…

4. 1) The Rationale:  Titanium-Nitride-Oxide Coating Absolute Lowest Thrombogenicity Effective Restenosis Reduction Shortest DAP Therapy  Helicoidal Design Improved Trackability & Crossability The Stent of Choice in ACS

5. 2) The Clinical Evidence… Titan2 vs. The Latest DES Generation

6. The BASE-ACS Randomized Trial BAS vs EES 12- Month Clinical Follow-Up TiTAN-2 XIENCE-V SOURCE: The BASE-ACS Randomized Controlled Trial Late Breaking Trial EuroPCR 2011

7. The BASE-ACS Randomized Trial  ACS Population  827 Patients  100% Patients Follow-Up SOURCE: The BASE-ACS Randomized Controlled Trial Late Breaking Trial EuroPCR 2011 Titan2 vs. The Latest DES Generation

8. The BASE-ACS RCT MACE @ 12 months MACE: Cardiac Death, nonfatal MI or TLR 7.2% 2.6% 6.8% 3.9% TITAN-2 XIENCE-V % Months after Index Procedure % P non-inferiority = 0.001 HR 0.94 (0.59-1.50)

9. TiTAN2 is Non-Inferior to XIENCE V at 12 months The BASE-ACS RCT MACE (%) P non-inferiority = 0.001 TiTAN-2 XIENCE-V

10. The BASE-ACS Randomized Trial BAS vs EES 18- Month Clinical Follow-Up TiTAN-2 XIENCE-V SOURCE: The BASE-ACS Randomized Controlled Trial Late Breaking Trial ASIA PCR 2012

11. The BASE-ACS RCT MACE: Cardiac Death, nonfatal MI or TLR 7.2% 2.6% 6.8% 3.9% TITAN-2 XIENCE-V % % MACE @ 18 months Months after Index Procedure

12. The BASE-ACS RCT MACE @ 18 months MACE: Cardiac Death, nonfatal MI or TLR 7.2% 2.6% 6.8% 3.9% Days after Index Procedure TITAN-2 XIENCE-V % P = 0.74 HR 0.96 (0.78-1.18)

13. TiTAN2 vs. XIENCE V at 18 months The BASE-ACS RCT MACE (%) P = 0.74 P = 0.01 P = 0.021 * Definite & Probable AMI (%) *Thrombosis (%) TiTAN-2 XIENCE-V TiTAN-2 XIENCE-V TiTAN-2 XIENCE-V

14. The BASE-ACS RCT Titan2 vs. The Latest DES Generation * Definite & Probable  At 12 months Titan-2 BAS demonstrates its Non-Inferiority vs. Xience-V EES in terms of MACE (9.6% vs 9.0%) in patients with ACS  At 18 months Titan2-BAS improves its MACE score vs. EES (10.8% vs. 11.7%) due to a significantly better safety profile in terms of hard clinical endpoints: AMI (2.6% vs. 6.3%, p=0.01) Thrombosis* (1.2% vs. 3.7%, p=0.021) (with significantly less DAPT duration: 8.7 vs.10.2 months, p<0.001)

15. The Evidence-Based Choice for Your ACS patients !

16. All cited trademarks are the property of their respective owners. This material is not intended for use in the United-States and certain other countries. Caution: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. ©2012 Hexacath or its affiliates.